OR5M8

Across TCGA pan-cancer cohorts, OR5M8 Mutation is linked to patient survival in 7 of 34 cancer types, making it a survival-associated OR5M8 data layer compared with 10 for mass-spec protein.

The strongest signal is observed in liver hepatocellular carcinoma (LIHC), where higher OR5M8 Mutation is associated with worse disease-free survival. In most high-consensus cancer types, elevated OR5M8 expression acts as an unfavorable survival marker.

LIHC, LGG, and LUAD are the cancer types where OR5M8 Mutation most reproducibly stratifies survival.

Mutation survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
LIHC	DFS	Median	All	0.063	0.544	<.001	24	view →
LGG	DFS	Median	All	0.083	0.833	<.001	12	view →
LUAD	DFS	Median	IV	0.342	0.893	<.001	7	view →
UCS	DFS	Median	All	0.126	0.523	.009	6	view →
SARC	OS	Median	All	0.210	0.745	.014	6	view →
BLCA	OS	Median	III,IV	0.051	0.684	<.001	6	view →
COAD	OS	Median	All	0.755	0.872	.037	2	view →

Pink = unfavorable, green = favorable. Showing the 7 strongest of 7 lineages.

OR5M8–LIHC (DFS)

Open the LIHC breakdown →